Parvovirus compositions and related methods for gene therapy
AssigneeCarbon Biosciences, Inc.
InventorsRobert Kotin, Sebastian Aguirre Kozlouski, Carolyn Pelletier
Life of this patent
Estimating the term…
Abstract
The present disclosure provides technologies comprising parvovirus compositions, preparations, constructs, and methods for gene therapy.
Claims143
A construct comprising a VP1 capsid coding sequence encoding a parvovirus VP1 capsid polypeptide (e.g., a VP1 capsid polypeptide, e.g., a variant VP1 capsid polypeptide) (e.g., wild type or otherwise functional, e.g., codon optimized);
- and one or more of the following:
- (i) an expression control sequence (e.g., operably linked to the VP1 capsid coding sequence),
- (ii) a 5′ untranslated region (UTR) sequence,
- (iii) an alternative translation initiation codon sequence (e.g., wherein the VP1 capsid coding sequence comprises the alternative translation initiation codon),
- (iv) wherein the VP1 capsid coding sequence comprises fewer ATG sequence(s) across the length of the VP1 capsid coding sequence, relative to a parvovirus reference VP1 capsid coding sequence selected from the group consisting of those in Table 3A, or
- (v) any combination thereof.
The construct of any one of the preceding claims, wherein the alternative translation initiation codon sequence comprises a sequence according to CTG, TTG, ACG, or ATC.
The construct of any one of the preceding claims, wherein the one or more of (i)-(v) directs translation start at the alternative translation initiation codon sequence.
The construct of any one of the preceding claims, further comprising a sequence that encodes a parvovirus VP2 capsid polypeptide (e.g., a reference VP2 capsid polypeptide, e.g., a variant VP2 capsid polypeptide) (e.g., wherein the sequence that encodes a parvovirus VP2 capsid polypeptide is or comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:
- 195).
The construct of any one of the preceding claims, further comprising a parvovirus VP3 capsid polypeptide.
The construct of any one of the preceding claims, further comprising a heterologous peptide tag.
The construct of any one of the preceding claims, wherein the construct further comprises a nucleic acid sequence that encodes one or more heterologous peptides having a length from about 10 amino acids to 20 amino acids (e.g., according to SEQ ID NOs:
- 8-87) (e.g., wherein the one or more heterologous peptides comprises or is a heterologous targeting peptide).
The construct of any one of the preceding claims, wherein the parvovirus VP1 capsid polypeptide comprises a nuclear localization signal sequence (NLS).
The construct of any one of the preceding claims, wherein the parvovirus VP1 capsid polypeptide is a protoparvovirus VP1 capsid polypeptide, a bocaparvovirus VP1 capsid polypeptide, an erythroparvovirus VP1 capsid polypeptide, a tetraparvovirus VP1 capsid polypeptide, or a copiparvovirus VP1 capsid polypeptide.
The construct of any one of the preceding claims, wherein the construct reduces toxicity in a host cell, relative to a reference construct lacking (i)-(v).
The construct of any one of the preceding claims, wherein the construct increases virion production in a host cell, relative to a reference construct lacking (i)-(v).
The construct of any one of the preceding claims, wherein the construct increases capsid polypeptide yield in a host cell, relative to a reference construct lacking (i)-(v).
The construct of any one of the preceding claims, wherein the parvovirus VP1 capsid polypeptide comprises an amino acid sequence with at least 60% identity to an amino acid sequence in Table 3B.
The construct of any of the preceding claims, wherein the parvovirus VP1 capsid polypeptide diminishes human humoral immune response against a virion, and/or reduces neutralization of a virion by human antibodies.
A construct comprising a sequence having at least 70% identity (e.g., 80%, 85%, 90%, 95%, 100% identity) to a sequence in Table 4 (e.g., wherein the sequence comprises or is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:
- 171) (e.g., wherein the sequence comprises or is least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identical to SEQ ID NO:
- 178) (e.g., wherein sequence comprises or is least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identical to SEQ ID NO:
- 194) (e.g., wherein sequence comprises or is least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identical to SEQ ID NO:
- 195).
Dependencies are inferred from the claim text.